Enhertu Approved by FDA for HR-Positive, HER2-Low Breast Cancer
Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) jointly announced that their co-developed antibody-drug...
Drug
FDA Clears sBLA for Eisai and Biogen’s Leqembi Maintenance Dosing
Partners Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have announced that the...
Guangzhou Innogen’s Efsubaglutide Alfa Approved by NMPA for Type 2 Diabetes
China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd, a biopharma focused on metabolic diseases, has announced...
MSD and Eisai’s Keytruda/Lenvima Combo Shows Promise in Gastroesophageal Cancer Study
Partners Merck, Sharp & Dohme (MSD, NYSE: MRK) and Eisai (TYO: 4523) have announced the...
Novo Nordisk’s Amycretin Shows Promising Weight Loss Results in Phase Ib/IIa Study
Denmark – based pharmaceutical giant Novo Nordisk A / S (NYSE: NVO) has announced topline...
Boehringer Ingelheim’s Nerandomilast Granted Priority Review for IPF in China
German pharmaceutical giant Boehringer Ingelheim has announced that the Center for Drug Evaluation (CDE) of...
Shenzhen Kangtai Halts COVID-19 Vaccine Development Amid Market Shifts
Shenzhen based biopharmaceutical company Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the...
China Medical System Partners with MabGeek for Innovative Drug MG-K10
China Medical System Holdings (CMS; HKG: 0867) has announced a new license agreement with MabGeek...
BioCity Biopharma Launches Phase III Study for Kidney Disease Drug SC0062
BioCity Biopharma, a leading biopharmaceutical company, has announced the initiation of a Phase III clinical...
Hengrui’s Long-Acting Insulin Analogue Accepted for Review by China’s NMPA
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that its market filing for...
Shenzhen Beike Initiates First Chinese Stem Cell Study for Systemic Lupus Erythematosus
China-based stem cell specialist Shenzhen Beike Biotechnology Co., Ltd has announced the initiation of a...
United Laboratories’ Biosimilar Semaglutide Accepted for Review by China’s NMPA
Hong Kong-listed United Laboratories International Holdings Ltd (HKG: 3933) has announced that its market filing...
Beijing Aosaikang’s ASKB589 Shows Promise in Phase I/II Study for Gastric Cancer
China’s Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has unveiled the latest results from a...
Biogen’s Higher-Dose Spinraza Regimen Under Review by FDA and EMA
US-based biopharmaceutical company Biogen (NASDAQ: BIIB) has submitted supplemental New Drug Applications (sNDAs) to the...
YolTech Initiates Study for YOLT-204 in Transfusion-Dependent Beta-Thalassemia
Shanghai-based YolTech Therapeutics, a biotech startup specializing in lipid nanoparticle delivery and gene editing, has...
Haichang Bio’s siRNA Drug HC016 Cleared for US Clinical Trials
China-based Zhejiang Haichang Biotech Co., Ltd has announced that its siRNA drug, HC016 complex lipid,...
Abbott Labs Posts Q4 Growth, Projects Strong 2025 Outlook
US-based Abbott Laboratories (NYSE: ABT) has released its Q4 2024 financial results, reporting an 8.8%...
Haisco’s HSK44459 Approved for Clinical Trials in Behcet’s Disease
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving clinical trial approval from...
Belief BioMed’s BBM-D101 Receives FDA Approval for DMD Clinical Trial
China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced receiving clinical trial approval from...
United Laboratories’ UBT251 Approved for Phase II Trials in Chronic Kidney Disease
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has announced receiving approval from the...